Please assess the completion status of the following clinical trial:

Trial Title: A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-80 years of age;~* rheumatoid arthritis after inadequate response to \>=1 DMARD treatment;~* active disease;~* DMARDs other than methotrexate withdrawn for at least 4 weeks prior to start of study treatment.~Exclusion Criteria:~* autoimmune disease other than rheumatoid arthritis;~* bone/joint surgery within 8 weeks prior to screening, or joint surgery planned within 24 weeks of MabThera infusion;~* concurrent treatment with any DMARD or antiTNF-alfa;~* intra-articular or parenteral corticosteroids within 4 weeks prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- MabThera/Rituxan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).